Published: 2025/11/10 05:11:47

Immune-Autonomous Cancer Therapy Shows Promise Using Bacteria

Researchers at the University of Tokyo have developed a novel cancer therapy that utilizes genetically engineered bacteria to directly target and destroy tumors, offering a potential breakthrough for patients with compromised immune systems. This innovative approach bypasses the need for a functioning immune response, addressing a critical gap in current cancer treatments.

How the Therapy Works

The research, led by Professor Hiroki Miyako, focuses on modifying Escherichia coli bacteria to specifically infiltrate and accumulate within tumor tissues. These bacteria are engineered to produce an enzyme that converts a prodrug – an inactive medication – into its active, cytotoxic form directly within the tumor microenvironment. This localized activation minimizes systemic toxicity, a common side effect of customary chemotherapy. The bacteria themselves are not harmful to healthy tissues.

“Conventional cancer immunotherapies rely on the patient’s immune system to recognize and attack cancer cells,” explains professor Miyako. “However,many patients,notably those undergoing chemotherapy or with pre-existing immune deficiencies,have weakened immune systems,rendering these treatments ineffective. Our approach offers a solution by directly targeting the tumor, independent of the immune system’s capabilities.”

Overcoming Limitations of Existing Treatments

Current cancer treatments, such as chemotherapy and radiation, often damage both cancerous and healthy cells, leading to significant side effects.Immunotherapies, while promising, are ineffective for patients with suppressed immune function. This new bacterial therapy offers a targeted approach that minimizes damage to healthy tissues and works even when the immune system is compromised.It addresses a significant unmet need in cancer care, particularly for patients who haven’t responded to traditional immune-dependent treatments.

Promising Results in Preclinical Studies

In preclinical studies conducted on mice with weakened immune systems, the bacterial therapy demonstrated a significant reduction in tumor size and improved survival rates. The researchers observed that the engineered bacteria effectively colonized tumors and activated the prodrug, leading to targeted cancer cell death. The study, published in Nature Biomedical engineering, details the efficacy and safety of this approach.

Toward Clinical Trials and a New Era in Cancer Therapy

“We are preparing to launch a startup to advance this technology and hope to begin clinical trials within six years,” explained Professor Miyako. “A new chapter in bacteria-based cancer therapy — pursued for over 150 years — is finally beginning.”

This groundbreaking method marks a turning point for cancer patients with weakened immune systems. It offers a long-sought option where conventional immunotherapies fall short, signaling the arrival of truly immune-independent cancer treatment.

Key Takeaways

• This therapy uses engineered E. coli bacteria to directly target and destroy tumors.
• It bypasses the need for a functioning immune system, making it suitable for patients with compromised immunity.
• The bacteria activate a prodrug specifically within the tumor, minimizing systemic toxicity.
• Preclinical studies have shown significant tumor reduction and improved survival rates in mice.
• Clinical trials are planned to begin within six years.